AustralianSuper Pty Ltd Acquires Shares of 323,443 Amneal Pharmaceuticals, Inc. $AMRX

AustralianSuper Pty Ltd bought a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 3rd quarter, Holdings Channel.com reports. The firm bought 323,443 shares of the company’s stock, valued at approximately $3,238,000.

Several other hedge funds and other institutional investors have also made changes to their positions in AMRX. Mirae Asset Global Investments Co. Ltd. raised its holdings in Amneal Pharmaceuticals by 16.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company’s stock worth $98,000 after purchasing an additional 1,735 shares in the last quarter. Rafferty Asset Management LLC increased its position in Amneal Pharmaceuticals by 22.0% during the 2nd quarter. Rafferty Asset Management LLC now owns 16,984 shares of the company’s stock worth $137,000 after purchasing an additional 3,066 shares during the period. Exchange Traded Concepts LLC purchased a new position in shares of Amneal Pharmaceuticals during the 3rd quarter worth approximately $31,000. SG Americas Securities LLC lifted its holdings in shares of Amneal Pharmaceuticals by 3.5% in the 2nd quarter. SG Americas Securities LLC now owns 99,129 shares of the company’s stock valued at $802,000 after buying an additional 3,368 shares during the period. Finally, Janney Montgomery Scott LLC boosted its stake in shares of Amneal Pharmaceuticals by 19.6% in the second quarter. Janney Montgomery Scott LLC now owns 23,150 shares of the company’s stock valued at $187,000 after buying an additional 3,800 shares in the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Down 3.0%

NASDAQ:AMRX opened at $13.68 on Friday. Amneal Pharmaceuticals, Inc. has a 52-week low of $6.68 and a 52-week high of $15.00. The stock has a fifty day simple moving average of $12.82 and a 200-day simple moving average of $10.83. The company has a market capitalization of $4.30 billion, a PE ratio of 684.34 and a beta of 1.34.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The firm had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals had a net margin of 0.20% and a negative return on equity of 185.60%. As a group, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Analysts Set New Price Targets

AMRX has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Truist Financial set a $15.00 price target on shares of Amneal Pharmaceuticals in a report on Wednesday, January 7th. Piper Sandler reissued an “overweight” rating and set a $13.00 price objective (up previously from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Finally, Barclays started coverage on shares of Amneal Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $15.00 target price on the stock. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.80.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Ted C. Nark sold 50,000 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $11.72, for a total value of $586,000.00. Following the sale, the director directly owned 291,029 shares in the company, valued at $3,410,859.88. This represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Nikita Shah sold 131,856 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total value of $1,571,723.52. Following the transaction, the executive vice president owned 146,403 shares of the company’s stock, valued at $1,745,123.76. This represents a 47.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 231,856 shares of company stock worth $2,743,724 over the last quarter. Company insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.